- Home
- IOBT vs CRIS Comparison
IOBT vs CRIS Comparison
Compare IOBT & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | CRIS |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 14.0M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | IOBT | CRIS |
|---|---|---|
| Price | $0.04 | $0.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 40.5M | 780.6K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.77 | ★ 91.57 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.03 | $0.49 |
| 52 Week High | $2.79 | $3.13 |
Technical Indicators
Market Signals| Indicator | IOBT | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 41.96 |
| Support Level | N/A | $0.49 |
| Resistance Level | $0.22 | $0.79 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.92 | 33.92 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.